Member Info for achilles

Its disgraceful the bod raised at 1p, SP was around 3.5p early December so why didnt they do a raise then?? Why wait till SP has retraced and raise at a ridiculous 50% discount??

Last years raise was 3.7p at 5% discount, why raise at 50% discount now?? Absolutely disgusting, Matthew walls is a total disgrace

1p placing?? Fcking bunch of crooks

Slowly creeping up now, way too cheap at this price

Definitely oversold now, cant believe its back to 2p after all the recent good news

Maven capital still selling it seems, once they are out and we get news on FDA approval this will re-rate

Wow 10 bagger in a week, wtf?!

FDA approval due in Q1 2026, this will easily be 10p+

CARDIO inCode-Score® distribution with Sohin Genetics, Mexico

Commercial agreement to distribute CARDIO inCode-Score® for the genetic risk prediction and prevention of coronary heart disease

Decent price - 0.76p

Completion of Warrant Offering

Further to the announcement released by the Company on 5 December 2025 (the "Initial Announcement"), the Board of Anglesey is pleased to announce that the investment of £350,000 in Anglesey by Energold Minerals Inc ("Energold"), through the purchase of non-voting exchangeable warrants (the "Warrants" and the "Warrant Offering"), has completed.

Pursuant to the binding letter of intent ("LOI") entered into between the parties, Energold agreed to invest £350,000 in Anglesey through the Warrant Offering. The price per Warrant was based on the 5-day volume weighted average price ("VWAP") of ordinary shares of Anglesey ("Ordinary Shares"), for the period up to the close of business on 8 December 2025 (the "Pricing Date"). Accordingly, based on the VWAP for that period of 0.7597 pence per share (representing a premium of approximately 153% to the closing price of 0.30 pence per Ordinary Share on 4 December 2025

Massive buys in the background, should break 1p again soon

By the time these placing shares are churned through there will be a new placing, never ending placing here just like ORCP

Maven reducing their holding, its bonkers after two massive RNS last week and collab with Thermo Fisher the mcap now is only £8 million!

Madness selling now, this is worth 2 - 3p minimum before government funding

Massive rerate coming up

MiningLamp 5 Dec '25

Here is a more detail breakdown of in ground value - total gross value at current prices $3.4 billion.

Contained Metals & Gross Value

Copper: 16.9 Mt × 1% = 169,000 t → ~$1.44 billion

Zinc: 16.9 Mt × 2% = 338,000 t → ~$0.85 billion

Lead: 16.9 Mt × 1% = 169,000 t → ~$0.36 billion

Silver: 16.9 Mt × 30 g/t = ~16.3 million oz → ~$0.41 billion

Gold: 16.9 Mt × 0.3 g/t = ~163,000 oz → ~$0.33 billion

Total Gross In-Situ Value $3.4 billion USD

Copper stocks are poised to do well due to strong, long-term demand from the green energy transition (EVs, renewables, data centers) colliding with tight supply, leading to expected price increases, supported by analyst forecasts predicting significant price targets and a growing supply deficit, benefiting miners through higher revenues and potential dividends.

With copper price near all time high, the copper deposit alone in Parys mountain is worth a staggering $1.5 billion

Mcap here is ridiculous low at £3.8 million, Cornish metal is £100 million. AYM will rerate to £15 - 20 million very soon

Cavendish note released today, target price 11.5p

GENinCode* Collaboration with Thermo Fisher Scientific GENinCode has announced a collaboration with Thermo Fisher Scientific, to sell, distribute and manufacture the company’s CARDIO inCode-Score polygenic test for the prediction and prevention of coronary heart disease. We expect this partnership to support and accelerate the adoption and commercialisation of CARDIO inCode, particularly in the US and EMEA, where Thermo Fisher has a significant platform presence for testing. We believe the collaboration provides strong validation of GENinCode’s technology and the CARDIO inCodeScore test, which has seen a number of clinical studies published, highlighting the test’s ability to identify patients at greater risk of coronary heart disease based on their genetic risk. There is a growing body of evidence supporting the use of genetic data alongside traditional risk assessments to better predict and prevent heart disease, the leading cause of death globally.

Investment thesis: We believe GENinCode is making strong progress within its three target regions. The Thermo Fisher collaboration validates the opportunity for CARDIO inCode in the US, while the company develops its UK and EU strategies, including the launch of the ROCA test in the UK. With a large and global patient population to target, clinical statements recognising the importance of polygenic risk scores for heart disease and a broadly unaddressed genetic testing market for cardiovascular disease, we believe GENinCode remains well-placed in the emerging market of cardiovascular genetic risk assessment.

Thanks Bjet, I bought 3 more tranches this morning, hopefully we will get more NHS news soon as well and we can all make some serious money!

Bought more at 3.4 and 3.52, rude not to